NCT02550197View on ClinicalTrials.gov

Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years

PHASE3CompletedINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

July 31, 2016

Conditions

Influenza

Interventions

BIOLOGICAL

Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016

0.5 mL, Intramuscular

BIOLOGICAL

Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation

0.5 mL, Intramuscular

Trial Locations (5)

425-707

Ansan-si

400-712

Incheon

120-752

Seoul

150-950

Seoul

152-840

Seoul

All Listed Sponsors

lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT02550197 - Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years | Biotech Hunter | Biotech Hunter